|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
14 September 2015 |
|
Main ID: |
NCT01094912 |
|
Date of registration:
|
26/03/2010 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Procedures of Locoregional Analgesia and Quality of Life in Palliative Care Units
TALViSoP |
|
Scientific title:
|
Procedures of Locoregional Analgesia and Quality of Life in Palliative Care |
|
Date of first enrolment:
|
April 2010 |
|
Target sample size:
|
38 |
|
Recruitment status: |
Suspended |
|
URL:
|
https://clinicaltrials.gov/show/NCT01094912 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
France
| | | | | | | |
|
Contacts
|
|
Name:
|
Gérard TERRIER, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
CHU Limoges |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patient = 18 years-old, male or female, whatever his/her ethnic group
- Patient with untreatable cancer
- Patient hospitalized in a palliative care unit, with a life expectancy = 1 week
- Pain unresponsive to conventional treatments
- Effectiveness of the injection test
- Signed informed consent
Exclusion Criteria:
- Patients > 18 years-old
- Patients with pain other than cancer pain
- Patient's refusal
- Coagulation disorders
- Local infection
- Known hypersensitivity to local analgesics
- Inefficacy of the injection test.
- Contraindication for analgesics
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Pain
|
|
Intervention(s)
|
|
Drug: opioids
|
|
Primary Outcome(s)
|
|
Change in patients global quality of life
[Time Frame: 1 week after first injection]
|
|
Secondary Outcome(s)
|
|
change in patient's global quality of life
[Time Frame: 2 days and 1 week after procedure]
|
|
Secondary ID(s)
|
|
I08014/TALViSoP
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|